Jeffrey T. Ha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jeffrey T. Ha has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Min Jun
The George Institute for Global Health University of New South Wales Sydney New South Wales Australia
4 shared publications - Sunil V. Badve
The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia
4 shared publications Amit X. Garg
3 shared publications- Martin Gallagher
The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia
3 shared publications - Meg J. Jardine
NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
3 shared publications Vlado Perkovic
3 shared publications
Latest Publications
- 19 June 2026
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
Sex disparities in receiving evidence-based medications in patients with CKD
Background and hypothesis: Chronic kidney disease (CKD) is a growing global health burden. While studies have demonstrated sex disparities in CKD prevalence and outcomes, evidence on sex-based differences in therapeutic management remains limited. This analysis aims to assess sex disparities in the receipt of evidence-based medications in a global CKD cohort. Methods: This study is a substudy of the Global Kidney Patient Trials Network, a prospective, observational, international cohort of CKD patients. The exposure of this study is biological sex, and the main outcomes are the receipt of evidence-based medications for CKD, including renin–angiotensin system inhibitors (RASis), sodium–glucose co-transporter 2 inhibitor (SGLT2i), and diuretics. Adjusted multivariable logistic models were conducted to examine associations between sex and proportion of receiving medications, as well as the interactions between sex and other key clinical characteristics (advanced age, high Kidney Disease: Improving Global Outcomes prognosis risk, and comorbid condition). Results: A total of 4192 participants were eligible, and 40.9% were female. Females had lower odds of receiving RASi [odds ratio (OR) = 0.75, 95% confidence interval (CI) 0.64–0.88; P < .001] and SGLT2i (OR = 0.79, 95% CI 0.64–0.98; P = .03) compared to males, after adjusting for age, region, systolic blood pressure, body mass index, presence of cardiovascular disease and diabetes, CKD aetiology, and prognosis risk, with no significant difference in the receipt of diuretics. There were no significant interactions between sex and any other key clinical characteristics, indicating that the disparities in the receipt of RASi and SGLT2i remained consistent across high-risk subgroups. Conclusion: Female patients with CKD are less likely to receive evidence-based medications than males, irrespective of established CKD risk factors. This difference highlights potential inequities in treatment globally that may result in outcome disparities.
- 19 June 2026
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
Sex disparities in receiving evidence-based medications in patients with CKD
Background and hypothesis: Chronic kidney disease (CKD) is a growing global health burden. While studies have demonstrated sex disparities in CKD prevalence and outcomes, evidence on sex-based differences in therapeutic management remains limited. This analysis aims to assess sex disparities in the receipt of evidence-based medications in a global CKD cohort. Methods: This study is a substudy of the Global Kidney Patient Trials Network, a prospective, observational, international cohort of CKD patients. The exposure of this study is biological sex, and the main outcomes are the receipt of evidence-based medications for CKD, including renin–angiotensin system inhibitors (RASis), sodium–glucose co-transporter 2 inhibitor (SGLT2i), and diuretics. Adjusted multivariable logistic models were conducted to examine associations between sex and proportion of receiving medications, as well as the interactions between sex and other key clinical characteristics (advanced age, high Kidney Disease: Improving Global Outcomes prognosis risk, and comorbid condition). Results: A total of 4192 participants were eligible, and 40.9% were female. Females had lower odds of receiving RASi [odds ratio (OR) = 0.75, 95% confidence interval (CI) 0.64–0.88; P < .001] and SGLT2i (OR = 0.79, 95% CI 0.64–0.98; P = .03) compared to males, after adjusting for age, region, systolic blood pressure, body mass index, presence of cardiovascular disease and diabetes, CKD aetiology, and prognosis risk, with no significant difference in the receipt of diuretics. There were no significant interactions between sex and any other key clinical characteristics, indicating that the disparities in the receipt of RASi and SGLT2i remained consistent across high-risk subgroups. Conclusion: Female patients with CKD are less likely to receive evidence-based medications than males, irrespective of established CKD risk factors. This difference highlights potential inequities in treatment globally that may result in outcome disparities.
- Open Access
- 1 April 2026
- Published by Wiley in Nephrology
- Vol. 31 (4) , e70202
Six‐Weekly Versus Monthly Haemodialysis Blood Testing in an Australian Tertiary Kidney Service: A Quality, Safety, Green Nephrology Initiative and Cost‐Saving Analysis
There is limited evidence to guide optimal frequency of surveillance bloodwork for haemodialysis patients. In September 2023, surveillance bloodwork frequency was reduced from monthly to 6‐weekly across 4 Illawarra‐Shoalhaven dialysis units. We retrospectively evaluated actual frequency of blood tests, safety (all‐cause hospitalisations, hospitalisations for hyperkalaemia, percentage of potassium and haemoglobin levels in target ranges), cost‐savings and environmental impact (reduction in carbon emissions and waste generation) of 6‐weekly versus monthly scheduled bloodwork for clinically stable patients receiving in‐facility haemodialysis during the 12‐months before and after this practice change. Staff perspectives were gathered via survey. We analysed 99 patients with monthly surveillance bloodwork and 101 patients with 6‐weekly bloodwork. After reducing to 6‐weekly scheduled bloodwork, frequency of FBC/EUC/CMP blood tests decreased from 48.3 to 34.9 per patient‐year. Comparing 6‐weekly versus monthly groups, there was no increase in percentage of patients with ≥ 1 hospitalisation (72% vs. 73.5%, p = 0.70), hospitalisation for hyperkalaemia (0.8% vs. 0.9%, p = 0.92); percentage of patients with potassium levels (3.5–5.9 mmol/L) was similar (86.0% vs. 86.2%, p = 0.88). Proportion of haemoglobin levels in target range (100–115 g/L) decreased from 45.4% to 38.5% ( p < 0.01) but with no clear changes in Erythropoietin Stimulating Agent use. Overall, there were 3.8 fewer blood draws, 8.7 fewer blood tubes used, $AUD201.44 saved in pathology costs and carbon emissions reduced by 1.03 kg per patient‐year. Of 58 dialysis nurses, 47 (81%) responded to a survey and indicated the practice change was acceptable (38/47, 81%). Reducing surveillance bloodwork frequency to 6‐weekly for haemodialysis patients delivered substantial cost‐savings and had positive environmental benefits without compromising safety. Strong engagement with dialysis staff supports its scalability and sustainability.
- 1 April 2026
- Published by Wiley in Nephrology
- Vol. 31 (4) , e70202
Open AccessSix‐Weekly Versus Monthly Haemodialysis Blood Testing in an Australian Tertiary Kidney Service: A Quality, Safety, Green Nephrology Initiative and Cost‐Saving Analysis
There is limited evidence to guide optimal frequency of surveillance bloodwork for haemodialysis patients. In September 2023, surveillance bloodwork frequency was reduced from monthly to 6‐weekly across 4 Illawarra‐Shoalhaven dialysis units. We retrospectively evaluated actual frequency of blood tests, safety (all‐cause hospitalisations, hospitalisations for hyperkalaemia, percentage of potassium and haemoglobin levels in target ranges), cost‐savings and environmental impact (reduction in carbon emissions and waste generation) of 6‐weekly versus monthly scheduled bloodwork for clinically stable patients receiving in‐facility haemodialysis during the 12‐months before and after this practice change. Staff perspectives were gathered via survey. We analysed 99 patients with monthly surveillance bloodwork and 101 patients with 6‐weekly bloodwork. After reducing to 6‐weekly scheduled bloodwork, frequency of FBC/EUC/CMP blood tests decreased from 48.3 to 34.9 per patient‐year. Comparing 6‐weekly versus monthly groups, there was no increase in percentage of patients with ≥ 1 hospitalisation (72% vs. 73.5%, p = 0.70), hospitalisation for hyperkalaemia (0.8% vs. 0.9%, p = 0.92); percentage of patients with potassium levels (3.5–5.9 mmol/L) was similar (86.0% vs. 86.2%, p = 0.88). Proportion of haemoglobin levels in target range (100–115 g/L) decreased from 45.4% to 38.5% ( p < 0.01) but with no clear changes in Erythropoietin Stimulating Agent use. Overall, there were 3.8 fewer blood draws, 8.7 fewer blood tubes used, $AUD201.44 saved in pathology costs and carbon emissions reduced by 1.03 kg per patient‐year. Of 58 dialysis nurses, 47 (81%) responded to a survey and indicated the practice change was acceptable (38/47, 81%). Reducing surveillance bloodwork frequency to 6‐weekly for haemodialysis patients delivered substantial cost‐savings and had positive environmental benefits without compromising safety. Strong engagement with dialysis staff supports its scalability and sustainability.
- 9 February 2026
- Published by S. Karger AG in American Journal of Nephrology
- p. 1-11
Methods Article for a Study Protocol: Study Design and Baseline Characteristics of the Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) Trial
Introduction: Patients with advanced stages of chronic kidney disease (CKD) and dialysis-dependent kidney failure are at a greater risk of cardiovascular events and mortality than those with early stages of CKD. There are no completed definitive randomized trials on the safety and efficacy of anticoagulant therapy in this patient population. Methods: Treatment of cardiovascular disease with low-dose Rivaroxaban in Advanced Chronic Kidney disease (TRACK) is a multicenter, randomized, placebo-controlled trial (NCT03969953), designed to enroll 1,886 adult participants with CKD stage 4 or 5 (estimated glomerular filtration rate ≤29 mL/min/1.73 m2) or dialysis-dependent kidney failure and high cardiovascular risk (defined as at least one of the following risk factors; coronary artery disease, nonhemorrhagic non-lacunar stroke, peripheral artery disease [PAD], diabetes mellitus, or age ≥65 years). Participants are randomized to rivaroxaban 2.5 mg twice daily or matching placebo. The primary efficacy outcome is a composite of cardiovascular death, myocardial infarction, stroke, or PAD event. The primary safety outcome is major bleeding, defined as a composite of fatal bleeding, bleeding leading to hospitalization, or symptomatic bleeding in a critical area or organ. From January 2021 to July 2025, 1,458 eligible participants (mean age 63.2 years, 700 [48%] age ≥65 years, 432 [29.6%] women, 715 [49%] dialysis-dependent kidney failure and 743 [51%] CKD stage 4 or 5, 1,125 [77.2%] diabetes mellitus, 674 [46.2%] treated with aspirin at baseline) underwent randomization. Conclusion: TRACK will evaluate the effect of low dose rivaroxaban on major adverse cardiovascular events in participants with CKD stages 4 and 5 and dialysis-dependent kidney failure, and elevated cardiovascular risk.
- 9 February 2026
- Published by S. Karger AG in American Journal of Nephrology
- p. 1-11
Methods Article for a Study Protocol: Study Design and Baseline Characteristics of the Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) Trial
Introduction: Patients with advanced stages of chronic kidney disease (CKD) and dialysis-dependent kidney failure are at a greater risk of cardiovascular events and mortality than those with early stages of CKD. There are no completed definitive randomized trials on the safety and efficacy of anticoagulant therapy in this patient population. Methods: Treatment of cardiovascular disease with low-dose Rivaroxaban in Advanced Chronic Kidney disease (TRACK) is a multicenter, randomized, placebo-controlled trial (NCT03969953), designed to enroll 1,886 adult participants with CKD stage 4 or 5 (estimated glomerular filtration rate ≤29 mL/min/1.73 m2) or dialysis-dependent kidney failure and high cardiovascular risk (defined as at least one of the following risk factors; coronary artery disease, nonhemorrhagic non-lacunar stroke, peripheral artery disease [PAD], diabetes mellitus, or age ≥65 years). Participants are randomized to rivaroxaban 2.5 mg twice daily or matching placebo. The primary efficacy outcome is a composite of cardiovascular death, myocardial infarction, stroke, or PAD event. The primary safety outcome is major bleeding, defined as a composite of fatal bleeding, bleeding leading to hospitalization, or symptomatic bleeding in a critical area or organ. From January 2021 to July 2025, 1,458 eligible participants (mean age 63.2 years, 700 [48%] age ≥65 years, 432 [29.6%] women, 715 [49%] dialysis-dependent kidney failure and 743 [51%] CKD stage 4 or 5, 1,125 [77.2%] diabetes mellitus, 674 [46.2%] treated with aspirin at baseline) underwent randomization. Conclusion: TRACK will evaluate the effect of low dose rivaroxaban on major adverse cardiovascular events in participants with CKD stages 4 and 5 and dialysis-dependent kidney failure, and elevated cardiovascular risk.
- Open Access
- 27 October 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (2) , 312-320
Variability in eGFR and the Risk of Adverse Kidney Outcomes and All-Cause Mortality
Key Points: Increased eGFR variability over 3 years independently predicts a higher risk of kidney outcomes and all-cause mortality. This association remained consistent across subgroups and sensitivity analyses. Routine eGFR variability assessment may enable identification of high-risk patients and provide an opportunity for the initiation of interventions. Background: eGFR variability may predict adverse outcomes, such as cardiovascular events and mortality, yet its influence on kidney impairment progression in routine clinical practice is not well described. Methods: This retrospective cohort study used longitudinal eGFR data from MedicineInsight, a comprehensive primary care database. We included adults (18 years or older) with at least three eGFR measurements over 3 years between January 1, 2011, and December 31, 2018. eGFR variability between visits was assessed using the coefficient of variation and categorized into groups by quintiles. A kidney composite end point, comprising a sustained 40% decline in eGFR from baseline, a sustained eGFR of 2 , and all-cause mortality, was tracked over a 3-year follow-up. Cox proportional hazards models quantified the association between eGFR variability and outcomes. Results: Among 754,306 patients, with a mean age of 59.1 years and 58.0% female, higher eGFR variability was associated with an increased risk of the kidney composite end point (hazard ratio, 2.17;95% confidence interval, 2.03 to 2.32) for the highest versus lowest fifth after adjusting for mean eGFR and eGFR slope, as well as other cardiovascular disease risk factors and medication use. Similar trends were observed for components of the primary outcome and across all subgroups including age, sex, hypertension, diabetes, and baseline eGFR. Conclusions: Increased eGFR variability independently predicts adverse kidney outcomes, underscoring its potential as a clinical biomarker for identifying high-risk patients. Including eGFR variability in routine kidney assessments may improve risk stratification, enabling timely interventions and potentially enhancing patient outcomes in primary care.
- 27 October 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (2) , 312-320
Open AccessVariability in eGFR and the Risk of Adverse Kidney Outcomes and All-Cause Mortality
Key Points: Increased eGFR variability over 3 years independently predicts a higher risk of kidney outcomes and all-cause mortality. This association remained consistent across subgroups and sensitivity analyses. Routine eGFR variability assessment may enable identification of high-risk patients and provide an opportunity for the initiation of interventions. Background: eGFR variability may predict adverse outcomes, such as cardiovascular events and mortality, yet its influence on kidney impairment progression in routine clinical practice is not well described. Methods: This retrospective cohort study used longitudinal eGFR data from MedicineInsight, a comprehensive primary care database. We included adults (18 years or older) with at least three eGFR measurements over 3 years between January 1, 2011, and December 31, 2018. eGFR variability between visits was assessed using the coefficient of variation and categorized into groups by quintiles. A kidney composite end point, comprising a sustained 40% decline in eGFR from baseline, a sustained eGFR of 2 , and all-cause mortality, was tracked over a 3-year follow-up. Cox proportional hazards models quantified the association between eGFR variability and outcomes. Results: Among 754,306 patients, with a mean age of 59.1 years and 58.0% female, higher eGFR variability was associated with an increased risk of the kidney composite end point (hazard ratio, 2.17;95% confidence interval, 2.03 to 2.32) for the highest versus lowest fifth after adjusting for mean eGFR and eGFR slope, as well as other cardiovascular disease risk factors and medication use. Similar trends were observed for components of the primary outcome and across all subgroups including age, sex, hypertension, diabetes, and baseline eGFR. Conclusions: Increased eGFR variability independently predicts adverse kidney outcomes, underscoring its potential as a clinical biomarker for identifying high-risk patients. Including eGFR variability in routine kidney assessments may improve risk stratification, enabling timely interventions and potentially enhancing patient outcomes in primary care.
- 3 July 2025
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 32 (1) , 151-156
Albuminuria, Kidney Function and Heart Failure Risk in Type 2 Diabetes: Participant-level Pooled Analysis from the CANVAS Program and CREDENCE Trial
- 3 July 2025
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 32 (1) , 151-156
Albuminuria, Kidney Function and Heart Failure Risk in Type 2 Diabetes: Participant-level Pooled Analysis from the CANVAS Program and CREDENCE Trial
- Open Access
- 9 April 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (9) , 1510-1521
Safety and Effectiveness of Apixaban versus Warfarin by Kidney Function in Atrial Fibrillation
Key Points: This real-world study involved a large cohort of 38,598 adults with atrial fibrillation from five jurisdictions across Australia and Canada. This study supports the use of apixaban as a safe and effective alternative to warfarin for atrial fibrillation across differing levels of kidney function. This study also adds important safety data on the use of apixaban in patients with reduced kidney function. Background: Evidence to guide the use of apixaban in people with atrial fibrillation (AF) and CKD in routine clinical practice has been limited. We assessed comparative safety (major bleeding) and effectiveness (ischemic stroke and death) of apixaban versus warfarin in patients with AF across the spectrum of non–dialysis-dependent CKD using large, routinely collected data. Methods: We combined findings from five retrospective cohorts (2013–2018) across Australia and Canada. Adults with AF, new dispensation of apixaban or warfarin, and a recorded eGFR grouped as ≥60, 45–59, 30–44, and 2 were included. Patients on dialysis or kidney transplant recipients were excluded. We assessed outcomes within 1 year of initiating either therapy: (1) composite of all-cause death, ischemic stroke, or transient ischemic attack and (2) first hospitalization for major bleeding (intracranial, gastrointestinal, or other). Cox models estimated hazard ratios (HRs; 95% confidence intervals) for outcomes across eGFR categories, after 1:1 matching using propensity scores. We summarized center-level data using random effects meta-analysis. Results: Among 38,598 matched apixaban and warfarin users, there were 4130 (10.7%) ischemic and 697 (1.8%) bleeding events within 1 year. Apixaban was associated with lower or similar risk for the ischemic outcome compared with warfarin in all eGFR categories (pooled HRs [95% confidence interval]: 0.78 [0.64 to 0.94], 0.77 [0.62 to 0.97], 0.82 [0.68 to 0.98], and 0.99 [0.68 to 1.45] for eGFR ≥60, 45–59, 30–44, and 2, respectively). Apixaban was associated with lower or similar risk of bleeding across the range of kidney function (pooled HRs: 0.55 [0.43 to 0.69], 0.73 [0.52 to 1.02], 0.55 [0.31 to 0.97], and 0.68 [0.47 to 0.99], respectively). There was no significant heterogeneity across jurisdictions or eGFR categories. Conclusions: In adults with AF and non–dialysis-dependent CKD, apixaban compared with warfarin was associated with lower or similar risk of ischemic and bleeding outcomes. Our results suggest that apixaban offers a favorable risk-benefit ratio in patients with AF independent of kidney function.
- 9 April 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (9) , 1510-1521
Open AccessSafety and Effectiveness of Apixaban versus Warfarin by Kidney Function in Atrial Fibrillation
Key Points: This real-world study involved a large cohort of 38,598 adults with atrial fibrillation from five jurisdictions across Australia and Canada. This study supports the use of apixaban as a safe and effective alternative to warfarin for atrial fibrillation across differing levels of kidney function. This study also adds important safety data on the use of apixaban in patients with reduced kidney function. Background: Evidence to guide the use of apixaban in people with atrial fibrillation (AF) and CKD in routine clinical practice has been limited. We assessed comparative safety (major bleeding) and effectiveness (ischemic stroke and death) of apixaban versus warfarin in patients with AF across the spectrum of non–dialysis-dependent CKD using large, routinely collected data. Methods: We combined findings from five retrospective cohorts (2013–2018) across Australia and Canada. Adults with AF, new dispensation of apixaban or warfarin, and a recorded eGFR grouped as ≥60, 45–59, 30–44, and 2 were included. Patients on dialysis or kidney transplant recipients were excluded. We assessed outcomes within 1 year of initiating either therapy: (1) composite of all-cause death, ischemic stroke, or transient ischemic attack and (2) first hospitalization for major bleeding (intracranial, gastrointestinal, or other). Cox models estimated hazard ratios (HRs; 95% confidence intervals) for outcomes across eGFR categories, after 1:1 matching using propensity scores. We summarized center-level data using random effects meta-analysis. Results: Among 38,598 matched apixaban and warfarin users, there were 4130 (10.7%) ischemic and 697 (1.8%) bleeding events within 1 year. Apixaban was associated with lower or similar risk for the ischemic outcome compared with warfarin in all eGFR categories (pooled HRs [95% confidence interval]: 0.78 [0.64 to 0.94], 0.77 [0.62 to 0.97], 0.82 [0.68 to 0.98], and 0.99 [0.68 to 1.45] for eGFR ≥60, 45–59, 30–44, and 2, respectively). Apixaban was associated with lower or similar risk of bleeding across the range of kidney function (pooled HRs: 0.55 [0.43 to 0.69], 0.73 [0.52 to 1.02], 0.55 [0.31 to 0.97], and 0.68 [0.47 to 0.99], respectively). There was no significant heterogeneity across jurisdictions or eGFR categories. Conclusions: In adults with AF and non–dialysis-dependent CKD, apixaban compared with warfarin was associated with lower or similar risk of ischemic and bleeding outcomes. Our results suggest that apixaban offers a favorable risk-benefit ratio in patients with AF independent of kidney function.
- 28 September 2023
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 83 (3) , 350-359.e1
Kidney Function, Albuminuria, and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis
- 28 September 2023
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 83 (3) , 350-359.e1
Kidney Function, Albuminuria, and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis
- Open Access
- 17 May 2023
- Published by Elsevier in Kidney Medicine
- Vol. 5 (7) , 100675
Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and Canada
- 17 May 2023
- Published by Elsevier in Kidney Medicine
- Vol. 5 (7) , 100675
Open AccessSafety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and Canada
- 23 May 2018
- Published by CSIRO Publishing in Australian Journal of Primary Health
- Vol. 24 (3) , 256-262
Healthcare resource utilisation by patients with coronary heart disease receiving a lifestyle-focused text message support program: an analysis from the TEXT ME study
The ‘Tobacco, Exercise and Diet Messages’ (TEXT ME) study was a 6-month, single-centre randomised clinical trial (RCT) that found a text message support program improved levels of cardiovascular risk factors in patients with coronary heart disease (CHD). The current analyses examined whether receipt of text messages influenced participants’ engagement with conventional healthcare resources. The TEXT ME study database (N = 710) was linked with routinely collected health department databases. Number of doctor consultations, investigations and cardiac medication prescriptions in the two study groups were compared. The most frequently accessed health service was consultations with a General Practitioner (mean 7.1, s.d. 5.4). The numbers of medical consultations, biochemical tests or cardiac-specific investigations were similar between the study groups. There was at least one prescription registered for statin, ACEI/ARBs and ß-blockers in 79, 66 and 50% of patients respectively, with similar refill rates in both the study groups. The study identified TEXT ME text messaging program did not increase use of Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Scheme (PBS) captured healthcare services. The observed benefits of TEXT ME reflect direct effects of intervention independent of conventional healthcare resource engagement.
- 23 May 2018
- Published by CSIRO Publishing in Australian Journal of Primary Health
- Vol. 24 (3) , 256-262
Healthcare resource utilisation by patients with coronary heart disease receiving a lifestyle-focused text message support program: an analysis from the TEXT ME study
The ‘Tobacco, Exercise and Diet Messages’ (TEXT ME) study was a 6-month, single-centre randomised clinical trial (RCT) that found a text message support program improved levels of cardiovascular risk factors in patients with coronary heart disease (CHD). The current analyses examined whether receipt of text messages influenced participants’ engagement with conventional healthcare resources. The TEXT ME study database (N = 710) was linked with routinely collected health department databases. Number of doctor consultations, investigations and cardiac medication prescriptions in the two study groups were compared. The most frequently accessed health service was consultations with a General Practitioner (mean 7.1, s.d. 5.4). The numbers of medical consultations, biochemical tests or cardiac-specific investigations were similar between the study groups. There was at least one prescription registered for statin, ACEI/ARBs and ß-blockers in 79, 66 and 50% of patients respectively, with similar refill rates in both the study groups. The study identified TEXT ME text messaging program did not increase use of Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Scheme (PBS) captured healthcare services. The observed benefits of TEXT ME reflect direct effects of intervention independent of conventional healthcare resource engagement.